Anti-glomerular Basement Membrane Disease: epidemiological, clinical, laboratory, morphological, and immunophenotypic characteristics

Authors

DOI:

https://doi.org/10.61910/ricm.v8i2.520

Keywords:

Glomerulonephritis, Kidney Diseases, Anti-Glomerular Basement Membrane Disease, Biopsy, Fibrosis

Abstract

Introduction: Anti-glomerular basement membrane (anti-GBM) disease is a rare condition, classified as rapidly progressive glomerulonephritis (RPGN), with an annual incidence of less than 2 cases per million inhabitants. It is confirmed by renal biopsy showing crescents on light microscopy, which is associated with diffuse linear Ig Immunostaining along the glomerular basement membrane immunofluorescence. Prognosis depends on the severity of renal dysfunction at initial presentation, and timely diagnosis and early therapy are responsible for renal survival rates. Methods: A cross-sectional observational study was conducted using data collected from renal biopsy reports of 124 patients with RPGN. Results: The collected sample enabled the study to obtain a p-value <0.05 with significant associations. Patients with anti-GBM RPGN are predominantly male (72%). The mean age found was 46 years (Type I). Regarding the distribution of crescents, Class I showed crescents predominantly within the same evolutionary stage (proliferative or sclerosing). Regarding vascular thickness, vessels of normal thickness or slightly thickened prevailed. The degree of fibrosis was pronounced in 44% in Type I. Conclusion: New scientific data on this rare and poorly understood disease, especially in Brazil, were obtained. The morphological pattern showed that anti-GBM disease presents with severe evolutionary stages and pronounced tubulointerstitial involvement, requiring prompt treatment to improve renal and overall survival. 

References

Markowitz, Glen S., Jai Radhakrishnan, and Vivette D D'Agati. "An overlapping etiology of rapidly progressive glomerulonephritis." American journal of kidney diseases 43.2 (2004): 388-393.

McAdoo, Stephen P., and Charles D. Pusey. "Anti-glomerular basement membrane disease." Clinical Journal of the American Society of Nephrology 12.7 (2017): 1162-1172.

Shah MK, Hugghins SY. Characteristics and outcomes of patients with Goodpasture’s syndrome. South Med J. 2002;95(12):1411–1418.

Yang R, Hellmark T, Zhao J, et al. Antigen and epitope specificity of anti- glomerular basement membrane antibodies in patients with goodpasture disease with or without anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol. 2007;18(4):1338–1343.

Moulis G, Huart A, Guitard J, et al. IgA-mediated anti-glomerular basement membrane disease: an uncommon mechanism of Goodpasture's syndrome. Clin Kidney J. 2012;5:545–548. [PMC free article] [PubMed] [Google Scholar]

KussmanA,GoharaA.Serumantibody-negativeGoodpastureSyndromewith delta granule pool storage deficiency and eosinophilia. Clin Kidney J. 2012;5:572–575. [PMC free article] [PubMed] [Google Scholar]

Bomback, Andrew S. "Anti-glomerular basement membrane nephritis: why we still ‘need’the kidney biopsy." Nephrology Dialysis Transplantation Plus 5.6 (2012): 496-497.

Van Daalen EE, Jennette JC, McAdoo SP, et al. Predicting outcome in patients with anti-GBM glomerulonephritis. Clin J Am Soc Nephrol. 2018;13(1):63–72.

Cui Z, Zhao MH, Xin G, Wang HY. Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease. Nephron Clin Pract. 2005;99(2):c49–c55.

Chen M, Cui Z, Zhao MH. ANCA-associated vasculitis and anti-GBM disease: the experience in China. Nephrol Dial Transplant. 2010;25(7):2062–2065.

CRENSIGLOVA, Camila et al. Frequency and clinical histological analysis of glomerular diseases in a tertiary hospital in southern Brazil. Jornal Brasileiro de Nefrologia, [s.l.], v. 38, n. 1, p.42-48, 2016.

Prabhakar D, Rathi M, Nada R, Minz RW, Kumar V, Kohli HS, Jha V, Gupta KL. Anti-glomerular basement membrane disease: Case series from a tertiary center in North India. Indian J Nephrol. 2017 Mar-Apr;27(2):108-112. doi: 10.4103/0971-4065.171227. PMID: 28356661; PMCID: PMC5358149.

IVKOVIĆ, V.; BAJEMA, I. M.; KRONBICHLER, A. Beyond serology: Is there still a value of kidney biopsy in anti-glomerular basement membrane disease? Kidney international reports, v. 8, n. 12, p. 2495–2498, 2023.

Reggiani F, L'Imperio V, Calatroni M, Pagni F, Sinico RA. Goodpasture syndrome and anti-glomerular basement membrane disease. Clin Exp Rheumatol. 2023 Apr;41(4):964-974. doi: 10.55563/clinexprheumatol/tep3k5. Epub 2023 Mar 30. PMID: 36995324.

Hrušková Z, Tesař V. Pulmonaryrenal syndrome. Vnitr Lek. 2020 Spring;66(5):56-61. English. PMID: 32942871.

Segelmark M, Hellmark T. Anti-glomerular basement membrane disease: an update on subgroups, pathogenesis and therapies. Nephrol Dial Transplant. 2019 Nov 1;34(11):1826-1832. doi: 10.1093/ndt/gfy327. PMID: 30371823.

Asim M, Akhtar M. Epidemiology, Impact, and Management Strategies of Anti-Glomerular Basement Membrane Disease. Int J Nephrol Renovasc Dis. 2022 Apr 7;15:129-138. doi: 10.2147/IJNRD.S326427. PMID: 35418771; PMCID: PMC8999706.

Guo C, Ye M, Li S, Zhu TT, Rao XR. Anti-glomerular basement membrane disease with IgA nephropathy: A case report. World J Clin Cases. 2022 Apr 26;10(12):3916-3922. doi: 10.12998/wjcc.v10.i12.3916. PMID: 35647148; PMCID: PMC9100739.

Mami I, Ghzel E, Abida R, Hlaoui F, Jebali H, Rais L, Beji S, Hamida FB, Fatma LB, Zouaghi K. Anti-glomerular basement membrane disease with intense nephrotic syndrome: a new case report. Pan Afr Med J. 2021 Aug 16;39:243. doi: 10.11604/pamj.2021.39.243.30461. PMID: 34659616; PMCID: PMC8498661.

Ge Y, Liu K, Yang G, Yu X, Sun B, Zhang B, Yuan Y, Zeng M, Wang N, Xing C, Mao H. Clinicopathological characteristics and outcome predictors of anti-glomerular basement membrane glomerulonephritis. Ren Fail. 2022 Dec;44(1):2037-2045. doi: 10.1080/0886022X.2022.2147673. PMID: 36408940; PMCID: PMC9683053.

Marques C, Carvelli J, Biard L, Faguer S, Provôt F, Matignon M, Boffa JJ, Plaisier E, Hertig A, Touzot M, Moranne O, Belenfant X, Annane D, Quéméneur T, Cadranel J, Izzedine H, Bréchot N, Cacoub P, Piedrafita A, Jourde-Chiche N, Saadoun D. Prognostic Factors in Anti-glomerular Basement Membrane Disease: A Multicenter Study of 119 Patients. Front Immunol. 2019 Jul 18;10:1665. doi: 10.3389/fimmu.2019.01665. PMID: 31396214; PMCID: PMC6662558.

Yamashita M, Takayasu M, Maruyama H, Hirayama K. The Immunobiological Agents for Treatment of Antiglomerular Basement Membrane Disease. Medicina (Kaunas). 2023 Nov 16;59(11):2014. doi: 10.3390/medicina59112014. PMID: 38004064; PMCID: PMC10673378.

Fouhy F, Mayer N, Burke L, O'Shaughnessy M. Antiglomerular basement membrane (anti-GBM) disease with clinical and histological features that bridge the typical to atypical spectrum. BMJ Case Rep. 2021 Jul 13;14(7):e241883. doi: 10.1136/bcr-2021-241883. PMID: 34257112; PMCID: PMC8278913.

Kiani R, Shahid M. Anti-Glomerular Basement Membrane (Anti-Gbm) Disease - Effect of Early Diagnosis and Treatment on Prognosis. S D Med. 2020 May;73(5):208-211. PMID: 32579800.

Zhong Z, Tan J, Tang Y, Li Z, Qin W. Goodpasture syndrome manifesting as nephrotic-range proteinuria with anti-glomerular basement membrane antibody seronegativity: A case report. Medicine (Baltimore). 2020 Sep 25;99(39):e22341. doi: 10.1097/MD.0000000000022341. PMID: 32991448; PMCID: PMC7523814.

Peyton N, Rastogi P. Educational Case: Necrotizing and Crescentic Glomerulonephritis With Anti-Glomerular Basement Membrane Antibodies (Anti-Gbm). Acad Pathol. 2020 Dec 4;7:2374289520975166. doi: 10.1177/2374289520975166. PMID: 33330742; PMCID: PMC7720308.

Nikolopoulou A, Huang-Doran I, McAdoo SP, Griffith ME, Cook HT, Pusey CD. Membranous Glomerulonephritis With Crescents. Kidney Int Rep. 2019 Aug 13;4(11):1577-1584. doi: 10.1016/j.ekir.2019.07.021. PMID: 31890999; PMCID: PMC6933443.

Ivković V, Kronbichler A, Caza TN. "Atypical" Anti-GBM Disease: Just Atypical, or Not Anti-GBM Disease at All? Am J Kidney Dis. 2024 Jul;84(1):127-129. doi: 10.1053/j.ajkd.2024.02.011. Epub 2024 Apr 9. PMID: 38604267.

Anguiano L, Kain R, Anders HJ. The glomerular crescent: triggers, evolution, resolution, and implications for therapy. Curr Opin Nephrol Hypertens. 2020 May;29(3):302-309. doi: 10.1097/MNH.0000000000000596. PMID: 32132388; PMCID: PMC7170443.

Salama AD. IgA vasculitis and anti-GBM disease: two ends of a spectrum of immune complex vasculitis. Rheumatology (Oxford). 2020 May 1;59(Suppl 3):iii118-iii122. doi: 10.1093/rheumatology/kez540. PMID: 32348516.

Downloads

Published

07/16/2025